Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Filings indexed 590 across all filing types
Latest filing 2024-05-24 Director's Dealing
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (장내매수 - open market purchases) by an executive (Lee Doohyun) of Vivozon Pharmaceutical. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2024-05-24 Korean
전환가액의조정 (제20회차)
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under 'Capital/Financing Update' as it directly impacts the company's capital structure and potential future share dilution.
2024-05-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by an executive (Lee Doohyun) of Vivozon Pharmaceutical. This type of filing, which reports personal share transactions by company directors and executives, is classified as 'Director's Dealing' (DIRS).
2024-05-16 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the period 2024-01-01 to 2024-03-31, submitted to the Financial Services Commission and Korea Exchange. It contains detailed company information, business overview, capital changes, and financial data. This fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, special relationships, and collateral agreements (pledges) for the company 'Vivozon Pharmaceutical'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2024-05-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is used to disclose changes in shareholdings by major shareholders or insiders. In the provided taxonomy, this corresponds to 'Major Shareholding Notification' (MRQ), as it details a significant change in share ownership (specifically due to a stock consolidation/reverse split) by a major shareholder (Vaultea, Inc.).
2024-05-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.